GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Geraldine Vidhya VijayNa ZhaoPetra Den HollanderMike J ToneffRobiya JosephMika PietilaJoseph H TaubeTapasree R SarkarEsmeralda Ramirez-PenaSteven J WerdenMaryam ShariatiRuli GaoMary SobieskiClifford C StephanNathalie SphyrisNoayuki MiuraPeter DaviesJeffrey T ChangRama SoundararajanJeffrey M RosenSandurai A ManiPublished in: Breast cancer research : BCR (2019)
Taken together, our data demonstrate that GSK3β is a potential target for TNBCs and suggest that GSK3β inhibitors could serve as selective inhibitors of EMT and CSC properties for the treatment of a subset of aggressive TNBC. GSK3β inhibitors should be tested for use in combination with standard-of-care drugs in preclinical TNBC models.